Diagnostic Biomarkers Uncovered for Rare Kidney Cancer

U-M study combines local data with data from The Cancer Genome Atlas to discover novel biomarkers for chromophobe renal cell carcinoma through next-generation RNA sequencing.

2:40 PM

Author | Ian Demsky

Kidney cells strained

Renal cell carcinoma is the most common type of kidney cancer, accounting for about 90% of cases in adults. But there are more than 10 different subtypes, each with important differences at a molecular level that can shape their aggressiveness or their response to treatment.

Using next-generation RNA sequencing techniques, a team of scientists from the University of Michigan Rogel Cancer Center has uncovered the gene signature of chromophobe renal cell carcinoma (ChRCC) and have extensively tested the expression of three new biomarkers. The subtype is the third most common type of renal cell carcinoma, comprising about 5% of cases.

The U-M analysis, which appears in European Urology, examined RNA sequencing data from more than 1,000 kidney cancer samples combining profiles from Michigan Medicine patients with others in The Cancer Genome Atlas. 

"Our approach identified two genes — Forkhead Box I1 (FOXI1) and Rh family C glycoprotein (RHCG) — and one long non-coding RNA (LINC01187) that are overexpressed in chromophobe renal cell carcinoma and positive in related oncocytic tumors," says senior study author Rohit Mehra, M.D., an associate professor of pathology at Michigan Medicine and member of the Michigan Center for Translational Pathology.

"We investigated both cancers primary to the kidney as well as those which had spread out, and found strong expression of these three biomarkers," he adds. "Importantly, we did not find them to be associated with other subtypes of kidney cancer, especially in metastatic state."

Like Podcasts? Add the Michigan Medicine News Break to your Alexa-enabled device or subscribe for updates on iTunes, Google Play and Stitcher.

Follow-up work is being conducted to validate the new biomarkers for use in the clinic at U-M and beyond, Mehra notes, where they may be particularly useful in diagnosis of metastatic tumors or a subset of primary tumors that can't be readily identified under the microscope.

The success of the group's integrative sequencing analysis approach is helping them develop a more specific kidney cancer diagnostic panel to complement existing tools, Mehra says. He notes the approach allowed the group previously to identify a specific biomarker for another rare kidney cancer called mucinous tubular and spindle cell carcinoma, helping to aid the diagnosis of challenging samples from U-M and other institutions.

Our approach identified two genes — Forkhead Box I1 (FOXI1) and Rh family C glycoprotein (RHCG) — and one long non-coding RNA (LINC01187) that are overexpressed in chromophobe renal cell carcinoma.
Rohit Mehra, M.D.

The current analysis also points toward the type of cell within a normal kidney from where chromophobe renal cell carcinoma and related cancers originate — a specialized cell in the lining of the small tubules in the kidneys called an intercalated cell. This information could be helpful in future efforts to treat or better classify these tumors.

Importantly, the study also throws light on possible mechanisms that may underlie a variant of the disease called sarcomatoid ChRCC, where the scientists observed a complete lack of FOXI1 and long non-coding RNA. Loss of FOXI1, a key transcription factor, may contribute to de-differentiation in these tumors which tend to be more aggressive and may require additional therapeutic strategies.

The research was led by co-first authors Stephanie Skala, M.D, Xiaoming Wang, Ph.D., Yuping Zhang, Ph.D., and Rahul Mannan, M.B.B.S. The other senior authors include Arul Chinnaiyan. M.D., Ph.D., and Saravana Dhanasekaran, Ph.D.

The study was supported by the Michigan Prostate SPORE (2P50CA186786-06), National Cancer Institute (1U01CA214170-01, 1R35CA231996-01) and Michigan Medicine Department of Pathology.

Paper cited: "Next-Generation RNA Sequencing-Based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncoyctic Neoplasms," European Urology. DOI: 10.1016/j.eururo.2020.03.003

MORE FROM THE LAB: Subscribe to our weekly newsletter

 

 


More Articles About:

Lab Report Urological Cancer Cancer Research Cancer Diagnosis Cancer: Cancer Types
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.
Family with mom and dad and three kids sitting on a park bench, dad's arms extended around the family.
Health Lab

Intuition pushed mom to keep checking for breast cancer

Michigan mom had no reason to suspect cancer. But instinct nudged her to find out for sure — and carried her through challenging treatments to remission.
Perforin increases endosomal-mitochondrial contact sites in tumor cells. Left is without perforin; right has perforin.
Health Lab

Immune system protein is a cancer killer on its own, new study shows

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.
Three people stand arm in arm with backs to camera studying a wall of family mementos
Health Lab

Online resources and coaching helped people seek genetic testing for cancer

New study from researchers at the University of Michigan Rogel Cancer Center showed an online resource and phone-based coaching both helped increase rates of genetic testing.
Health Lab

Liver cancer can be preventable. Do you know the treatable risk factors?

Learn about the risks of chronic liver disease, the treatable liver disease factors and how rates of liver cancer have increased.